Abstract
A variety of cancer immunotherapy approaches aim at the induction of cytolytic T lymphocytes (CTLs) as main effector cells in anti-tumor immune responses. However, the mere existence of the tumor proves the failure of immune surveillance and points at immune response defects. Antigenicity is prerequisite for specific immunotherapy and has been proven or is suggested by indirect evidence for several tumors. The failure of the immune system to cope with the cancer in these cases must therefore be attributed to immune regulatory problems including immune suppression, the lack of costimulatory support, or, very importantly, the lack of T cell help for the induction of cytolytic T effector cells. In addition, to become instrumental for clinical application, immunotherapy protocols must be suitable for highly individualized treatments and applicable without lengthy preparations.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Altman JD, Moss PAH, Goulder PJR, et al (1996) Phenotypic analysis of antigen-specific T lymphocytes. Science 274: 94–96
Bennet SRM, Carbone FR, Karamalis F, Flavell RA, Miller JFAP, Heath WR (1998) Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature 393: 478–480
Boon T, Cerottini JC, Eynde B van den, Bruggen P van der, Pel A van (1994) Tumor antigens recognized by T lymphocytes. Annu Rev Immunol 12: 337–365
Borges E, Wiesmüller KH, Jung G, et al (1994) Efficacy of synthetic vaccines in the induction of cytotoxic T lymphocyte responses. J Immunol Methods 173: 253–263
Chen LP, Ashe S, Brady WA, et al (1992) Costimulation of anti-tumor immunity by the B7 counterreceptor for the T lymphocyte molecule CD28 and CTLA4. Cell 71: 1093–1102
Colombo MP, Mattei S, Parmiani G (1992) Cytokine gene transfer in tumor cells as an approach to antitumor therapy. Int J Lab Res 21: 278–282
Grabbe S, Beissert S, Schwarz T, et al (1995) Dendritic cells as initiators of tumor immune responses: a possible strategy for tumor immunotherapy? Immunol Today 16: 117–121
Guo YJ, Wu M, Chen H, et al (1994) Effective tumor vaccine generated by fusion of hepatoma cells with activated B cells. Science 263: 518–520
Juretic A, Malenica B, Juretic E, et al (1985) Helper effects required during in vivo priming for a cytolytic response to the H-Y antigen in nonresponder mice. J Immunol 134: 1408–1410
Kugler A, Seseke F, Thelen P, Kallerhoff M, Muller GA, Stuhler G, Muller C, Ringert RH (1998) Autologous and allogenic hybrid cell vaccine in patients with metastatic renal cell carcinoma. Br J Urol 82: 487–493
Lethe B, Eynde B van den, Pel A van, Corradin G, Boon T (1992) Mouse tumor rejection antigens P815 A and P815 B: two epitopes carried by a single peptide. Eur J Immunol 22: 2283–2288
Maas RA, Dullens HFH, DenOtter W (1993) Interleukin-2 in cancer treatment — disappointing or (still) promising. Cancer Immunol Immunther 66: 141–148
Mitchison NA (1990) An exact comparison between the efficiency of two-and three-cell-type clusters mediating helper activity. Eur J Immunol 20: 699–702
Mitchison NA, O’Malley C (1987) Three-cell-type clusters of T cells with an- tigen-presenting cells best explain the epitope linkage and noncognate requirements of the in vivo cytolytic response. Eur J Immunol 17: 1479–1483
Ridge JP, Di Rossa F, Matzinger P (1998) A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell. Nature 393: 474–478
Schoenberger SP, Toes REM, Voort EIH van der, Offringa R, Melief CJM (1998) T-cell help for cytotoxic T lymphocytes is mediated by CD40CD4OL interactions. Nature 393: 480–483
Stuhler G, Walden P (1993) Collaboration of helper and cytotoxic T lymphocytes. Eur J Immunol 23: 2279–2286
Stuhler G, Walden P (1994) Recruitment of helper T-cells for induction of tumor rejection by cytolytic T lymphocytes. Cancer Immunol Immunother 39: 342–345
Trefzer U, Weingart G, Chen YW, Audring H, Winter P, Guo YJ, Sterry W, Walden P (2000) Hybrid cell vaccination for cancer immunotherapy: first clinical trial with metastatic melanoma. Int J Cancer 85: 618–626
Young JW, Inaba K (1996) Dendritic cells as adjuvants for class I major histo- compatibility complex-restricted antitumor immunity. J Exp Med 183: 7–11
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2000 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Trefzer, U., Herberth, G., Sterry, W., Walden, P. (2000). The Hybrid Cell Vaccination Approach to Cancer lmmunotherapy. In: Walden, P., Sterry, W., Hennekes, H. (eds) Therapeutic Vaccination Strategies. Ernst Schering Research Foundation Workshop, vol 30. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-04183-3_10
Download citation
DOI: https://doi.org/10.1007/978-3-662-04183-3_10
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-662-04185-7
Online ISBN: 978-3-662-04183-3
eBook Packages: Springer Book Archive